作者机构：
湖南中医药大学中医诊断学湖南省重点实验室,湖南 长沙 410208;湖南中医药大学中医心肺病证辨证与药膳食疗重点研究室,湖南 长沙 410208;湖南中医药大学中医药防治眼耳鼻咽喉疾病湖南省重点实验室,湖南 长沙 410208;湖南中医药大学中医方证研究转化医学湖南省重点实验室,湖南 长沙 410208;[宋厚盼] Hunan Provincial Key Laboratory of Diagnostic Research in Chinese Medicine, Changsha, 410208, China, Key Laboratory of TCM Heart and Lung Syndrome Differentiation and Medicated Diet and Dietotherapy, Changsha, 410208, China, Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Eye, Ear, Nose and Throat Diseases, Changsha, 410208, China
摘要：
Hydrogen sulfide (H2S) is a very important third endogenously generated gaseous signaling molecule and plays a key role in physiological and pathological regulation processes of living biosystems. Although a lot of H2S fluorescent probes have been reported, the relationship between the physiology and pathology of H2S in inflamed tissues remains unclear. Herein, by adopting a donor-pi-acceptor (D-pi-A)-structured naphthalimide derivative as the two-photon (TP) fluorophore and a 4-dinitrobenzene-ether (DNB) with a strong intramolecular charge transfer (ICT) effect as the recognition moiety, we reported a novel TP bioimaging probe NP-H2S for H2S with improved sensitivity. The NP-H2S exhibits very low background fluorescence in the absence of H2S, and a significant 258-fold fluorescence intensity enhancement was observed in the presence of H2S, resulting in a high sensitivity and selectivity to H2S in aqueous solutions with a detection limit of 18.8 nM observed. The probe also shows a wide linear response concentration range (0-10.0 mu M) to H2S with high selectivity. All these features are favorable for direct monitoring of H2S in complex biological samples. It was then applied for direct TP imaging of H2S in tissues of inflammation model with satisfactory sensitivity, indicating it has the latent capability in further biological applications for investigation of the interaction H2S with inflammation. (C) 2020 Elsevier B.V. All rights reserved.
期刊：
Evidence-Based Complementary and Alternative Medicine,2021年2021 ISSN：1741-427X
通讯作者：
Li, Xiantao;Hu, Zhixi
作者机构：
[Fang, Ge; Fan, Xingyu; Liao, Xiaoqian] Hunan Univ Chinese Med, Coll Tradit Chinese Med, Changsha 410208, Peoples R China.;[Wang, Yaxin; Zhou, Xiaowen; Li, Xiantao; Yan, Zhenqian] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou 510006, Peoples R China.;[Hu, Zhixi] Hunan Univ Chinese Med, Inst Chinese Med Diag, Changsha 410208, Peoples R China.
通讯机构：
[Li, Xiantao] G;[Hu, Zhixi] H;Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou 510006, Peoples R China.;Hunan Univ Chinese Med, Inst Chinese Med Diag, Changsha 410208, Peoples R China.
摘要：
Background. Damp phlegm and blood stasis pattern (DPBSP) is the main pattern in coronary heart disease (CHD) patients. To quantify and standardize the diagnosis of DPBSP, questionnaires are usually administered. The CHD Damp Phlegm and Blood Stasis Pattern Questionnaire (CHD-DPBSPQ) is the standard metric for measuring CHD-DPBSP signs and symptoms in practice and clinical research. The CHD-DPBSPQ has moderate diagnostic efficiency, as evidenced by its receiver operating characteristic curves. Furthermore, and high reliability and validity have been shown in some studies but not in a multicenter clinical trial. Our purpose was to evaluate the test-retest reliability of a proprietary CHD-DPBSPQ. Methods. The CHD-DPBSPQ uses a standard procedure for measuring symptoms. The (interrater) reliability and validity of this questionnaire have been previously studied. Here, we evaluated the test interval and weighted kappa value of items of test-retest (intrarater) reliability of the CHD-DPBSPQ. The test-retest reliability was evaluated by the intraclass correlation coefficient (ICC) for the total CHD-DPBSPQ score and the phlegm domain and blood stasis domain scores. Weighted kappa statistics were calculated for the individual CHD-DPBSPQ items. Results. Using the CHD-DPBSPQ, 79 patients with late-stage CHD who were participating in a multicenter clinical trial were assessed twice. The ICCs for the CHD-DPBSPQ score were as follows: 0.827 for the total CHD-DPBSPQ, 0.778 for the phlegm domain score, and 0.828 for the blood stasis domain score. The reliability was slightly better in patients whose test interval was <= 14 days. The weighted kappa values of individual items showed moderate consistency. Conclusions. The CHD-DPBSPQ was found to have excellent test-retest reliability in this sample of patients.
作者机构：
[Qi, Weiyu; Li, Xin; Yang, Yuying] Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.;[Cao, Jianzhong; Li, Xin] Hunan Univ Chinese Med, Hunan Prov Key Lab Diagnost Chinese Med, 300 Xueshi Rd, Changsha 410208, Hunan, Peoples R China.
通讯机构：
[Cao, Jianzhong] H;Hunan Univ Chinese Med, Hunan Prov Key Lab Diagnost Chinese Med, 300 Xueshi Rd, Changsha 410208, Hunan, Peoples R China.
关键词：
complementary and alternative medicine;COVID-19;delta variant;meta-analysis;Qingshu Yiqi decoction
摘要：
BACKGROUND: Qingshu Yiqi decoction combined with general western medicine are important and prevalent recently treatment method of corona virus disease 2019 (COVID-19) with Delta variant, but the efficacy and safety were not clear. This meta-analysis aims to clarify their clinical efficacy and safety thus to provide evidence for clinical application. METHODS: We searched Chinese databases CNKI, Wanfang, VIP and English databases PubMed, Cochrane Library, Embase for the current study. The retrieval time was from the establishment to November, 2021. Literature quality was evaluated according to the bias risk assessment criteria of Cochrane Collaboration network. RevMan 5.3 and Stata 12.0 were used to perform this research. RESULTS: The efficacy and safety of Qingshu Yiqi decoction combined with western medicine for COVID-19 with Delta variant were evaluated in terms of total effective rate, TCM syndrome score, negative conversation rate of viral nucleic acid, disappearance rate of clinical symptoms (such as fever, cough, and fatigue), CT improvement, white blood cell (WBC), lymphocyte (LYM) and adverse reaction rate. CONCLUSION: This study provides reliable evidence-based support for the clinical efficacy and safety of Qingshu Yiqi decoction as a complementary and alternative therapy for COVID-19 with Delta variant. PROSPERO REGISTRATION NUMBER: CRD42021271606.
